"mek inhibitor" trang 2 - tải miễn phí từ tailieunhanh
Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma
5    83    0
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-IMETRY): Protocol for a multicentre UK single arm phase II trial

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-IMETRY): Protocol for a multicentre UK single arm phase II trial
10    91    0
MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/ MEK/ERK signaling pathway

MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/ MEK/ERK signaling pathway
7    52    1
IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts

IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts
13    75    1
Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care

Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care
12    39    1
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
7    60    1
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
11    70    1
Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis

Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis
10    49    1
BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
12    34    1
Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways

Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways
15    69    1
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
11    58    1
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
10    59    1
Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma

Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma
9    43    1
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance
9    32    1
Diverse mechanisms activate the PI 3- kinase/mTOR pathway in melanomas: Implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Diverse mechanisms activate the PI 3- kinase/mTOR pathway in melanomas: Implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
12    54    1
Dual targeting of MEK and PI3K efectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with diferent genetic backgrounds

Dual targeting of MEK and PI3K efectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with diferent genetic backgrounds
12    38    1
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
12    54    1
A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
8    6    1
Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa
14    8    1
Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: A case report

Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: A case report
4    6    1